Efavirenz
DefinitionThis section has been translated automatically.
Virustatic. Non-nucleoside inhibitor of the reverse transcriptase of HIV.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in patients > 3 years.
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated in pregnancy (reproductive toxicity in animal tests, insufficient data available).
Dosage and method of useThis section has been translated automatically.
Adults/adolescents/children > 40 kg bw: 1 time/day 600 mg p.o. (in combination with protease inhibitors and/or nucleoside reverse transcriptase inhibitors (NRTI) of HIV.
Dose reduction in children > 3 yrs and patients < 40 kg bw: Pat. with 32.5-40 kg bw: 1 time/day 400 mg p.o., 25-32 kg bw: 1 time/day 350 mg p.o., 20-25 kg bw: 1 time/day 300 mg p.o., 15-20 kg bw: 1 time/day 250 mg p.o., 13-15 kg bw: 1 time/day 200 mg p.o.
Undesirable effectsThis section has been translated automatically.
Gastrointestinal symptoms like nausea (5-10% of patients), headache (5%), dizziness (5-10%), fatigue (5%), cutaneous NW (10-15% of patients) like erythema, erythema exsudativum multiforme, erythema nodosum, urticaria.
ContraindicationThis section has been translated automatically.
Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 3 years. Comedication with rifampicin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam) ergotamine derivatives, astemizole, etc.
PreparationsThis section has been translated automatically.
Sustiva